2001年，厦门大学化学专业，学士学位；
2006年，中科院上海有机化学研究所有机化学专业，博士学位；
2006-2011年，哈佛医学院Dana-Farber癌症研究所，博士后；
2011年至今，97国际至尊品牌源于信誉官网，闽江学者特聘教授/微生物药物课题组学科带头人；
2020年，获国家杰出青年科学基金资助。
B.S. 2001, Xiamen University, Chemistry;
Ph.D. 2006, Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Sciences, Organic Chemistry;
Research Fellow, Dana-Farber Cancer Institute, Harvard Medical School, 2006-2011;
Principal Investigator of Chemical Biology and Medicinal Chemistry Group, School of Life Sciences, Xiamen University, 2011 to Present.
团队专注药物发现的化学生物学研究，以解决未满足的临床需求为导向，针对创新药物研究中“药物靶标和先导化合物发现”的瓶颈问题，发展新化学小分子工具、鉴定新生物学靶标、提供新的干预手段，从学科交叉的角度提供突破瓶颈的方案。
研究主要包括：1）应用化学-生物合成融合的新化学空间构建；2）基于化学邻近诱导策略的难靶蛋白活性分子发现与功能验证；3）基于表型的新靶点发现与验证。通过上述研究完成创新药物发现实验室阶段的概念性验证，并与生物医药企业合作推进临床转化。
我们热忱欢迎对医学、生物学、化学和药学的前沿交叉领域感兴趣的志同道合者的加盟！
Our team focuses on chemical biology research for drug discovery, driven by the goal of addressing unmet medical needs. Addressing the key challenges in innovative drug development—specifically, the discovery of drug targets and lead compounds—we strive to develop novel small-molecule chemical tools, identify new biological targets, and provide innovative interventional strategies. By integrating interdisciplinary approaches, we aim to provide solutions that overcome these challenges.
Our research encompasses the following key areas: 1) the construction of expanded chemical space via the integration of chemical synthesis and biosynthesis; 2) the discovery and functional validation of bioactive molecules targeting previously undruggable proteins through chemical-induced proximity strategies; and 3) the identification and validation of novel targets for bioactive molecules via phenotypic screening. Through these efforts, we aim to achieve proof-of-concept validation at the laboratory stage of innovative drug discovery and collaborate with biomedical enterprises to facilitate clinical translation.
Warmly welcome motivated individuals with a keen interest in the interdisciplinary convergence of medicine, biology, chemistry, and pharmaceutical sciences to join us.
代表性论文(# co-first author, * Corresponding author):
专注药学发现的化学生物学研究。在基础研究方面：代表性成果以通讯、共同通讯作者在Nature (2022)、Cell (2019)、Nature Biotechnology (2025)、Nature Metabolism (2022)、Cell Reports Medicine (2025)、EMBO Molecular Medicine (2022)、Nature Communications (2018, 2020)、Science Translational Medicine (2016)、Cell Chemical Biology (2020)和Journal of Medicinal Chemistry (2018, 2025)等高水平期刊发表，其中2篇入选ESI高被引论文，1项成果获得2022年度“中国生命科学十大进展”。在转化应用方面：小分子药物发现共获8项发明专利的21件授权，包括美、日、欧等国外授权16件；实现技术成果转让5项，目前已有一个小分子药物在中国和美国开展临床试验（I期）。
1. Ma, T.; Tian, X.; Zhang, B.; Li, M.; Wang, Y.; Yang, C.; Wu, J.; Wei, X.; Qu, Q.; Yu, Y.; Long, S.; Feng, J.-W.; Li, C.; Zhang, C.; Xie, C.; Wu, Y.; Xu, Z.; Chen, J.; Yu, Y.; Huang, X.; He, Y.; Yao, L.; Zhang, L.; Zhu, M.; Wang, W.; Wang, Z.-C.; Zhang, M.; Bao, Y.; Jia, W.; Lin, S.-Y.; Ye, Z.; Piao, H.-L.; Deng, X.*; Zhang, C.-S.*; Lin, S.-C.*, Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature 2022, 603 (7899), 159-165. (Recommended by Faculty Opinions rated as exceptional).
2. Yin, C.; Zhu, B.; Zhang, T.; Liu, T.; Chen, S.; Liu, Y.; Li, X.; Miao, X.; Li, S.; Mi, X.; Zhang, J.; Li, L.; Wei, G.; Xu, Z.; Gao, X.; Huang, C.; Wei, Z.; Goding, C. R.; Wang, P.*; Deng, X.*; Cui, R.* Pharmacological targeting of STK19 inhibits oncogenic NRAS driven melanomagenesis. Cell, 2019, 176, 1113-1127.e16. (Highlighted by Cancer Discovery).
3. Chu, Y.; Chen, S.; Yang, M.; Chen, Y.; Fang, H.; Huang, P.; Xie, Y.; Sun, C.; Chen, Y.; Zhang, B.; Li, L.; Mu, H.; Song, D.; Cheng, W.; Wang, C.; Jiang, W.; Xu, X.; He, Z.; Chen, S.; Liu, M.; Ma, J.; Yang, M.; Cao, J.; Gao, J.; Shen, J.; Zhang, L.; Bai, Y.; Liu, Z.; Chen, J.; Dai, S.; Zeng, Y. A.; Zhao, Y.; Zhou, H.; Chen, C.; Ru, H.; Tan, L.; Chi, X.; Wang, F.; Gao, D.; Lin, M.; Deng, X.*; Jiang, H.*, A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2. Nat. Biotechnol. 2025. doi:10.1038 /s41587-025-02793-8 (Highlighted by Nat. Rev. Drug Discov. and Nat. Chem. Biol. )
4. Zhang, C. S.; Li, M.; Wang, Y.; Li, X.; Zong, Y.; Long, S.; Zhang, M.; Feng, J. W.; Wei, X.; Liu, Y. H.; Zhang, B.; Wu, J.; Zhang, C.; Lian, W.; Ma, T.; Tian, X.; Qu, Q.; Yu, Y.; Xiong, J.; Liu, D. T.; Wu, Z.; Zhu, M.; Xie, C.; Wu, Y.; Xu, Z.; Yang, C.; Chen, J.; Huang, G.; He, Q.; Huang, X.; Zhang, L.; Sun, X.; Liu, Q.; Ghafoor, A.; Gui, F.; Zheng, K.; Wang, W.; Wang, Z. C.; Yu, Y.; Zhao, Q.; Lin, S. Y.; Wang, Z. X.; Piao, H. L.; Deng, X.*; Lin, S.-C.*, The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK. Nat. Metab. 2022, 4 (10), 1369-1401.
5. Fan, F.; He, Z.; Kong, L. L.; Chen, Q.; Yuan, Q.; Zhang, S.; Ye, J.; Liu, H.; Sun, X.; Geng, J.; Yuan, L.; Hong, L.; Xiao, C.; Zhang, W.; Li, Y.; Wang, P.; Huang, L.; Wu, X.; Ji, Z.; Wu, Q.; Xia, N. S.; Gray, N. S.; Chen, L.; Yun, C. H.*; Deng, X.*; Zhou, D.* Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Sci. Transl. Med. 2016, 8, 352ra108. (Cover story, Highlighted by Nature Reviews Gastroenterology & Hepatology)
6. Li, L.*; Wang, Y.; Wang, Y.; Li, X.; Deng, Q.; Gao, F.; Lian, W.; Li, Y.; Gui, F.; Wei, Y.; Zhu, S. J.; Yun, C. H.; Zhang, L.; Hu, Z.; Xu, Q.; Wu, X.; Chen, L.; Zhou, D.; Zhang, J.; Xia, F.*; Deng, X.*, Dimeric natural product panepocyclinol A inhibits STAT3 via di-covalent modification. Acta Pharm. Sin. B 2025, 15 (1), 409-423.
7. Su, N.; Lian, W.; Zhang, B.; Tian, Y.; Li, L.; Chen, Y.; Zhi, X.; Zeng, T.; Wu, Q.; Chen, L.; Zhou, D.; Wang, H.-R.; Cheng, S.-C.; Li, L.*; Deng, X.*, Inhibiting NEDD4 in triple-negative breast cancer cells reprograms tumor immune microenvironment via the β-TrCP/YAP/ECM axis. Cell Rep. Med. 2025, 6 (10).
8. Lu, Y.; Fan, Z.; Zhu, S. J.; Huang, X.; Zhuang, Z.; Li, Y.; Deng, Z.; Gao, L.; Hong, X.; Zhang, T.; Li, L.; Sun, X.; Huang, W.; Zhang, J.; Liu, Y.; Zhang, B.; Jiang, J.; Gui, F.; Wang, Z.; Li, Q.; Song, S.; Huang, X.; Wu, Q.; Chen, L.; Zhou, D.; Zhang, J.*; Yun, C. H.*; Chen, L.*; Deng, X.*, A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC. EMBO Mol. Med. 2022, 14 (1), e14296. (Highlighted by ALK Positive Org. ).
9. Zhang, J.*; Bhuiyan, M. I. H.; Zhang, T.; Karimy, J. K.; Wu, Z.; Fiesler, V. M.; Zhang, J.; Huang, H.; Hasan, M. N.; Skrzypiec, A. E.; Mucha, M.; Duran, D.; Huang, W.; Pawlak, R.; Foley, L. M.; Hitchens, T. K.; Minnigh, M. B.; Poloyac, S. M.; Alper, S. L.; Molyneaux, B. J.; Trevelyan, A. J.; Kahle, K. T.*; Sun, D.*; Deng, X.*, Modulation of brain cation-Cl− cotransport via the SPAK kinase inhibitor ZT-1a. Nat. Commun. , 2020, 11, 78. (Highlighted by The Medical News).
10. Wang, Y.; Zhang, L.; Wei, Y.; Huang, W.; Li, L.; Wu, A. A.; Dastur, A.; Greninger, P.; Bray, W. M.; Zhang, C. S.; Li, M.; Lian, W.; Hu, Z.; Wang, X.; Liu, G.; Yao, L.; Guh, J. H.; Chen, L.; Wang, H. R.; Zhou, D.; Lin, S. C.; Xu, Q.; Shen, Y.; Zhang, J.; Jurica, M. S.; Benes, C. H.; Deng, X.*, Pharmacological Targeting of Vacuolar H(+)-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer. Cell Chem. Biol. 2020, 27 (11), 1359-1370.e8.
11. Wang, Y.; Jiang, Z.; Zhang, K.; Tang, H.; Wang, G.; Gao, J.; He, G.; Liang, B.; Li, L.; Yang, C.*; Deng, X.*, Whole-Tumor Clearing and Imaging of Intratumor Microbiota in Three Dimensions with miCDaL Strategy. Adv. Sci. 2024, 11 (44), 2400694.
12. Li, Y.; Liu, Z.; Li, L.; Lian, W.; He, Y.; Khalil, E.; Mäkilä, E.; Zhang, W.; Torrieri, G.; Liu, X.; Su, J.; Xiu, Y.; Fontana, F.; Salonen, J.; Hirvonen, J.; Liu, W.; Zhang, H.*; Santos, H. A.*; Deng, X.*, Tandem-Mass-Tag Based Proteomic Analysis Facilitates Analyzing Critical Factors of Porous Silicon Nanoparticles in Determining Their Biological Responses under Diseased Condition. Adv. Sci. 2020, 7 (15), 2001129.
13. Zhang, L.; Wang, Y.; Huang, W.; Wei, Y.; Jiang, Z.; Kong, L.; Wu, A. A.; Hu, Z.; Huang, H.; Xu, Q.; Li, L.; Deng, X.*, Biosynthesis and Chemical Diversification of Verucopeptin Leads to Structural and Functional Versatility. Org. Lett. 2020, 22 (11), 4366-4371.
14. Gui, F.; Jiang, J.; He, Z.; Li, L.; Li, Y.; Deng, Z.; Lu, Y.; Wu, X.; Chen, G.; Su, J.; Song, S.; Zhang, Y. M.; Yun, C. H.; Huang, X.; Weisberg, E.; Zhang, J.*; Deng, X.*, A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk(C481S) mutation in B-cell malignancies. Br. J. Pharmacol. 2019, 176, 4491-4509.
15. Wu, Z.; Liu, X.; Yan, X.-E.; Wu, X.; Huang, W.; Li, J.; Xiu, Y.; Lv, C.; Sun, C.; Wang, Z.; Xu, G.; Wu, X.; Hu, Z.; Huang, H.; Huang, X.; Zhang, J.*; Yun, C.-H.*; Li, L.*; Deng, X.*, Discovery of Potent and Selective Pyrrolo[2,3-d]pyrimidine Derivatives as Fourth-Generation EGFR Inhibitors Targeting Triple Mutations. J. Med. Chem. 2025, 68 (18), 19205-19228.
16. Huang, W.; Sun, X.; Li, Y.; He, Z.; Li, L.; Deng, Z.; Huang, X.; Han, S.; Zhang, T.; Zhong, J.; Wang, Z.; Xu, Q.; Zhang, J.; Deng, X.* Discovery and Identification of Small Molecules as Methuosis Inducers with in Vivo Antitumor Activities. J. Med. Chem. 2018, 61, 5424-5434.
17. Jiang, J.; Gui, F.; He, Z.; Li, L.; Li, Y.; Li, S.; Wu, X.; Deng, Z.; Sun, X.; Huang, X.; Huang, W.; Han, S.; Zhang, T.; Wang, Z.; Jiao, B.; Song, S.; Wang, H.-R.; Chen, L.; Zhou, D.; Liu, Q.; Ren, R.*; Zhang, J.*; Deng, X.* Targeting BRK-positive breast cancers with small molecule kinase inhibitors Cancer Res. 2017, 77, 175-186. (Highlighted by BioWorldTM).
18. Jiang, H.; He, H.; Chen, Y.; Huang, W.; Cheng, J.; Ye, J.; Wang, A.; Tao, J.; Wang, C.; Liu, Q.; Jin, T.; Jiang, W.*; Deng, X.*; Zhou, R.* Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J. Exp. Med. 2017, 214, 3219-3238. (Highlighted by Nature Reviews Rheumatology).
19. Deng, X. ¶; Dzamko, N. ¶; Prescott, A.; Davies, P.; Liu, Q.; Yang, Q.; Lee, J. D.; Patricelli, M. P.; Nomanbhoy, T. K.; Alessi, D. R.; Gray, N. S. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat. Chem. Biol. 2011, 7, 203-5.
20. Yang, Q. ¶; Deng, X. ¶; Lu, B. ¶; Cameron, M.; Fearns, C.; Patricelli, M. P.; Yates, J. R., 3rd; Gray, N. S.; Lee, J. D. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 2010, 18, 258-67.
参编《化学生物学》，ISBN：978-7-04-065666-4101，101计划教材
荣誉、奖励及参加学术团体的情况:
[1] 2017年，获福建省第十四届“青年科技奖”
[2] 2018年，获“药明康德生命化学研究奖”学者奖
[3] 2019年，获厦门大学“田昭武学科交叉奖”（特等奖）
[4] 2019年，获福建省自然科学奖一等奖（第三完成人）
[5] 2023年，获新基石科学基金会“科学探索奖”
[6] 2025年，获宝钢优秀教师奖
参加的主要学术团体
1. Acta pharmaceutica Sinica. B 编委
2. 中国生物化学与分子生物学会第十三届理事会，理事
3. 中国药学会药物化学专业委员会，委员
4. 全国卫生产业企业管理协会精准医疗分会，常务理事
5. 中国抗癌协会肿瘤分子医学专业委员会，常务委员
6. 中国高等教育学会科技服务专家指导委员会，委员
下载Firefox
